Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine...

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht...

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )

Prognostic model of all-cause mortality at 30 days in patients with cancer and...

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Metastatic breast cancer endpoints for survival: rwPFS and TTNT ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer

Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer ( Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France )

Nirogacestat demonstrates clinically significant improvement in PFS versus...

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

Scientists discover mechanism of action and an actionable inflammatory axis for...

Prof Charles Swanton - The Francis Crick Institute, London, UK

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC ( Prof Charles Swanton - The Francis Crick Institute, London, UK )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Olaparib continues to show positive results in advanced ovarian cancer - 7 year...

Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data ( Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA )

More from ecancer